Company Profile
AiViva is focused on developing targeted therapy for unmet needs in Ophthalmology, Dermatology, Urology, and Oncology. Our targeted approach is derived from our patented JEL™ technology, which allows treatment to be delivered directly to the source.
News & Media
Press Releases:
December 11, 2023
AiViva BioPharma Completes Phase 1 / 2 Clinical Trial of AIV001 for Administration in Patients with Nonmelanoma Skin Cancer
September 18, 2023
AiViva BioPharma Appoints Les Kaplan, to the Board of Directors
August 30, 2023
AiViva BioPharma Appoints Jung-Chin (Rongjin) Lin, to the Board of Directors
May 22, 2023
AiViva BioPharma Initiates Phase 1 Clinical Trial of AIV007 for Age-Related Macular
Degeneration and Diabetic Macular Edema
August 17, 2022
AiViva BioPharma Announces New Patent Received
October 2, 2020
AiViva BioPharma Initiates Phase 1 / 2 Clinical Trial of AIV001 for Nonmelanoma Skin Cancer
June 25, 2020
AiViva BioPharma Announces Positive Date from Phase 1 / 2a Clinical Trial of AIV001 for
Dermal Scarring and Wound Healing
News
AiViva BioPharma is Recognized by Life Sciences Review
Media
Partnerships
AiViva is dedicated to teaming with strategic partners and investors who share our vision and commitment to bring transformative therapies within our areas of focus in Ophthalmology, Dermatology, Urology, and Oncology. We also welcome the opportunity to explore novel applications of our JEL™ Technology in therapeutic areas of interest.
Please inquire by providing your contact information below: